/
BCRX
$10.00+$0.45 (+4.71%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$2.5B
254M shares
52-week range
$6.00 – $10.94
81% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.53%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-6.27
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.7M | $48.8M | $17.8M | $157.2M | $270.8M | $331.4M | $450.7M | $874.8M |
| Cost of revenue | $471.0K | $4.1M | $1.7M | $7.3M | $6.6M | $4.7M | $12.5M | $19.1M |
| Gross profit | $20.2M | $44.7M | $16.1M | $149.9M | $264.2M | $326.8M | $438.2M | $855.8M |
| Gross margin | 97.7% | 91.6% | 90.6% | 95.4% | 97.6% | 98.6% | 97.2% | 97.8% |
| R&D | $84.9M | $107.1M | $123.0M | $208.8M | $253.3M | $216.6M | $174.6M | $166.1M |
| Operating income | −$94.2M | −$99.5M | −$174.8M | −$177.7M | −$148.4M | −$103.7M | −$2.5M | $341.0M |
| EBITDA | −$90.4M | −$96.3M | −$167.6M | −$121.7M | −$143.9M | −$116.3M | $12.8M | $347.7M |
| Net income | −$101.3M | −$108.9M | −$182.8M | −$184.1M | −$247.1M | −$226.5M | −$88.9M | $263.9M |
| Net margin | -490.3% | -223.0% | -1026.4% | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% |
| EPS (diluted) | -0.98 | -0.94 | -1.09 | -1.03 | -1.33 | -1.18 | -0.43 | 1.21 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $671M | $-2.68 | $-2.83–$-2.52 | 4 |
| 2027 | $727M | $0.31 | $0.13–$0.42 | 4 |
| 2028 | $864M | $0.43 | $-0.05–$1.07 | 6 |
| 2029 | $1.1B | $0.91 | $0.85–$0.99 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
www.biocryst.com- Employees
- 435
- IPO / List date
- Mar 3, 1994
- HQ
- DURHAM, NC
Held by traders on TradeandTell
No one on the platform currently holds BCRX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 776,990 | $7.4M |
| Bridgewater Associatesas of 2026-03-31 | 638,054 | $6.1M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BCRX yet.
